

## **Zenicor-ECG once again selected for a screening project in the UK**

*Stockholm, October 24, 2017*

**Zenicor-ECG is once again the chosen system for screening in a NHS England setting. This time around an elderly population will be screened with the Zenicor ECG System while getting their annual flu vaccination shot. It is the first time that the Zenicor-ECG is used to search for atrial fibrillation in the context of a national immunisation programme.**

*- It is truly promising that the Zenicor ECG System has yet again been selected for an international screening project. Given the number of flu vaccinations given to the UK population each year, the demographics of the population targeted and how easy it is to use the Zenicor ECG System in this setting, we see great potential for this application, says Mats Palerius CEO of Zenicor.*

The annual flu vaccination is well established in the UK and is offered at pharmacies and at GPs in flu vaccination clinics. Flu shots are mainly offered to people over the age of 65 years, which is consistent with the risk group for stroke caused by atrial fibrillation. The flu shot clinics may therefore be a very well-suited environment for screening for atrial fibrillation.

The project uses Zenicor's new optimised work flow to take single timepoint ECGs. The workflow has been developed with care and has been recently been trialled at the University Hospital in Friborg, Switzerland. With the new work flow, more patients can be assessed in a very short time frame, which is required in the flu jab clinics where hundreds of patients pass through daily.

By trialling the Zenicor-ECG at three practises in the Bradford area, project leader and clinical director of The Willows Medical Practice, Dr Matthew Fay, hope to be able to effectively screen for atrial fibrillation using an existing care structure.

*-Zenicor's solutions make it easy and effective for us to detect and diagnose atrial fibrillation and other cardiac arrhythmias in a selected high-risk population, says Matthew Fay, Clinical Manager at The Willows Medical Practice and project manager for the project.*

## **About flu vaccinations in the UK**

- Flu vaccination is available every year in the NHS to help protect selected risk groups, such as those over 65 years of age, pregnant women and children and adults with impaired immune system or other chronic disease that weaken their general health, e.g. heart or lung diseases, throughout the flu season.
- England is one of the most pro-active countries in Europe in the field of flu vaccinations
- 75 per cent of those included in the selected risk group choose to receive the vaccination each year.

## **About Zenicor and the Zenicor-ECG**

Zenicor Medical Systems AB is a leading medical technology company in arrhythmia investigations and stroke prevention. Zenicor-ECG is optimised for cardiac arrhythmia diagnosis, including atrial fibrillation, in professional healthcare and the system is in use in over 350 clinics in ten countries all over Europe. The efficiency of the solution has been documented in several studies and articles published in internationally leading scientific journals. These studies have shown that Zenicor-ECG has superior diagnostic ability combined with cost-effectiveness and ease of use compared to traditional methods.

### **For more information, please contact:**

Mats Palerius, CEO, Zenicor Medical Systems AB,  
Phone: +46 70 561 55 64  
E-mail: [mats@zenicor.se](mailto:mats@zenicor.se)

Matthew Fay, GP Principal at the Willows Medical Practice, trustee AF association, UK and project lead

Phone: +44 7803050061

E-mail: [matthew.fay@bradford.nhs.uk](mailto:matthew.fay@bradford.nhs.uk)

About AF Association: <http://www.heartrhythmalliance.org/afa/uk/trustees-and-medical-advisory-committee-mac>

High resolution images of Zenicor ECG are available for download: <https://zenicor.com/news/>

*This information is such information that Zenicor Medical Systems AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 24th of October 2017.*